TY - JOUR
T1 - Experimentally induced nasal allergic responses
AU - Walden, Sandra M.
AU - Proud, David
AU - Bascom, Rebecca
AU - Lichtenstein, Lawrence M.
AU - Kagey-Sobotka, Anne
AU - Adkinson, N. Franklin
AU - Naclerio, Robert M.
N1 - Funding Information:
Supported by Grants NS 22488, HL 32272, AI 08270, and AI 20136 from the National Institutes of Health. Dr Walden is the recipient of the American Lung Association E. L. Trudeau Fel-lowship. Dr. Lichtenstein is the recipient of a Pfizer Biomedical Research Award. Dr. Naclerio is the recipient of Teacher Inves-tigator Development Award NS 00811 from the National Institute of Neurological and Communicative Disorders and Stroke.
PY - 1988/5
Y1 - 1988/5
N2 - To investigate the pathogenesis of allergic rhinitis, we developed a nasal challenge model in which we examined the early, late, and rechallenge responses to antigen provocation. In these three aspects of the allergic reaction the physiologic responses are associated with inflammatory mediator release. Whereas the early response appears to be related mainly to mast cell activation and mediator release, the late reaction involves a different pattern of mediator release and an inflammatory cell influx, consisting of basophils, neutrophils, and eosinophils. Rechallenge with antigen 11 hours later results in an augmented immediate response. Pretreatment with aspirin reduces the levels of cyclooxygenase metabolites in nasal secretions without affecting the immediate physiologic response to antigen or the expected increase in the levels of histamine, N-α-tosyl-l-arginine methyl ester-esterase activity, and leukotriene C4. Pretreatment with systemic steroids does not affect the early allergic response, but significantly reduces mediator release during the late and rechallenge responses. The influx of eosinophils is inhibited by pretreatment with systemic steroids, but neutrophil influx is not. In contrast, pretreatment with topical steroids blocks the early response and the late and rechallenge responses. Influx of all cell types, including the neutrophil, was prevented. These studies show unequivocally that an inflammatory process follows the initial response to antigen and that this inflammation is affected by drugs important in the treatment of chronic allergic disease. We speculate that understanding allergic inflammation will lead to new therapeutic development.
AB - To investigate the pathogenesis of allergic rhinitis, we developed a nasal challenge model in which we examined the early, late, and rechallenge responses to antigen provocation. In these three aspects of the allergic reaction the physiologic responses are associated with inflammatory mediator release. Whereas the early response appears to be related mainly to mast cell activation and mediator release, the late reaction involves a different pattern of mediator release and an inflammatory cell influx, consisting of basophils, neutrophils, and eosinophils. Rechallenge with antigen 11 hours later results in an augmented immediate response. Pretreatment with aspirin reduces the levels of cyclooxygenase metabolites in nasal secretions without affecting the immediate physiologic response to antigen or the expected increase in the levels of histamine, N-α-tosyl-l-arginine methyl ester-esterase activity, and leukotriene C4. Pretreatment with systemic steroids does not affect the early allergic response, but significantly reduces mediator release during the late and rechallenge responses. The influx of eosinophils is inhibited by pretreatment with systemic steroids, but neutrophil influx is not. In contrast, pretreatment with topical steroids blocks the early response and the late and rechallenge responses. Influx of all cell types, including the neutrophil, was prevented. These studies show unequivocally that an inflammatory process follows the initial response to antigen and that this inflammation is affected by drugs important in the treatment of chronic allergic disease. We speculate that understanding allergic inflammation will lead to new therapeutic development.
UR - http://www.scopus.com/inward/record.url?scp=0024007931&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0024007931&partnerID=8YFLogxK
U2 - 10.1016/0091-6749(88)90157-1
DO - 10.1016/0091-6749(88)90157-1
M3 - Article
C2 - 3372915
AN - SCOPUS:0024007931
SN - 0091-6749
VL - 81
SP - 940
EP - 949
JO - The Journal of allergy and clinical immunology
JF - The Journal of allergy and clinical immunology
IS - 5 PART 2
ER -